Today we confirmed the appointment of our latest partner hires as part of our expansion plans to open in Ireland.
The firm welcomes two new partners to open Taylor Wessing Ireland* with the support of UK partners James Goold and Alison Dennis.
Adam Griffiths, who was previously a member of the firm's private equity group and relocated to Ireland in 2017, has returned to Taylor Wessing to lead operations in Dublin.
Adam is a respected corporate lawyer in the region with experience in private equity and M&A transactions, with a focus on the international technology and life sciences…
Alderley Park, Cheshire – Infex Therapeutics is pressing ahead with a major development of its pandemic resilience strategy by today announcing an agreement with CRUK Newcastle Drug Discovery Unit. This will in-licence a novel therapy designed to treat SARS-CoV-2 along with future variants and a broad spectrum of coronaviruses.
The program, PAN-X, is an early stage drug that has shown encouraging activity during in-vitro testing.
It has been developed by a team led by Professor Mike Waring, Professor Steve Wedge and Professor Martin Noble at CRUK Newcastle Drug Discovery Unit at Newcastle…
Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge…
Introduction
I wanted to find out what it was like to work in scientific academia in the UK and then make the career move into industry, as this is what a lot of our job applicants have done or are currently considering. You may notice from my profile that I, however, have not done this career route myself so I spoke to people who have. I asked scientists CY Partners had helped into various pharmaceutical or Life Science companies for their insight and with their kind permission I am going to share the results here. They have lived it, and these are their views. My cohort spanned from fresh…
AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.Investigating the biological effects of a drug or doing proof of concept assay development, requires a source of the drug. Typically, it is difficult to obtain original pharmaceutical grade biotherapeutic drugs for research use, rather than a clinical application. Consequently, biological compounds almost identical to a reference biologic drug (biosimilars) that have been approved by governmental…
Enables accurate modelling of the human colon and the mucosal barrier
Provides new insights to the relationship between human microbiome and effect on human health
Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ microphysiological systems
Cambridge, UK, 27 July 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of…
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
Appointment supports international growth within ion channel contract research and drug discovery
Cambridge, UK, 26 July 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrion’s international customer base and facilitate entry into new territories.…
Reading Scientific Services Ltd (RSSL) has enhanced its Investigative and Quality Control (QC) capabilities with the installation of a new 600 MHz Bruker AVANCE NEO Nuclear Magnetic Resonance (NMR) spectrometer at its UK laboratories. The investment not only increases the scientific consultancy’s capacity to develop tailored analytical solutions, it also paves the way for further investigations into new NMR applications for the Life Science sectors.
The addition of the 600 MHz spectrometer is designed to strengthen and complement RSSL’s existing 400 MHz NMR instrument, which remains in…